Longeveron (LGVN) Competitors

LAVA Therapeutics (NASDAQ:LVTX) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership.

Is LVTX or LGVN more profitable?

LAVA Therapeutics has a net margin of 0.00% compared to Longeveron's net margin of -894.40%. Longeveron's return on equity of -95.91% beat LAVA Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LAVA Therapeutics	N/A	-106.29%	-38.24%
Longeveron	-894.40%	-95.91%	-79.69%

Which has higher valuation & earnings, LVTX or LGVN?

Longeveron has lower revenue, but higher earnings than LAVA Therapeutics. LAVA Therapeutics is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LAVA Therapeutics	$11.98M	3.34	-$25.11M	-$1.04	-1.46
Longeveron	$2.39M	4.83	-$15.97M	-$6.28	-0.12

Does the media prefer LVTX or LGVN?

In the previous week, Longeveron had 9 more articles in the media than LAVA Therapeutics. MarketBeat recorded 13 mentions for Longeveron and 4 mentions for LAVA Therapeutics. Longeveron's average media sentiment score of 0.22 beat LAVA Therapeutics' score of 0.20 indicating that Longeveron is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LAVA Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Longeveron	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more risk and volatility, LVTX or LGVN?

LAVA Therapeutics has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500. Comparatively, Longeveron has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500.

Do analysts prefer LVTX or LGVN?

LAVA Therapeutics presently has a consensus price target of $2.69, indicating a potential upside of 76.64%. Longeveron has a consensus price target of $7.25, indicating a potential upside of 853.95%. Given Longeveron's stronger consensus rating and higher probable upside, analysts plainly believe Longeveron is more favorable than LAVA Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LAVA Therapeutics	0 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Longeveron	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do institutionals and insiders have more ownership in LVTX or LGVN?

10.0% of Longeveron shares are owned by institutional investors. 9.5% of LAVA Therapeutics shares are owned by insiders. Comparatively, 11.2% of Longeveron shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Longeveron beats LAVA Therapeutics on 11 of the 16 factors compared between the two stocks.